Could COVID-19 be behind the rise in rare and aggressive cancers?
Since the pandemic, there has been a rise in new cancer cases, including rare and aggressive, late-stage cancers — and some physicians and researchers believe that COVID-19 may be behind this increase. Here's what you need to know.
Still No Evidence COVID-19 Vaccination Increases Cancer Risk, Despite Posts - FactCheck.org
It has not been shown that COVID-19 vaccines cause or accelerate cancer. Yet opponents of the vaccines say a new review article “has found that COVID-19 mRNA vaccines could aid cancer development.” The review conclusions are mainly based on the misinterpretation of a study on mRNA cancer vaccines in mice.
New study shows significant impacts of severe COVID-19 infection on
A new analysis from Oxford Population Health has found that pregnant women that are 30 years old or more, overweight, of mixed ethnicity or have gestational diabetes have a greater risk of
COVID-19 and pregnancy: a comprehensive study of comorbidities and outcomes - BMC Public Health
Objectives This study aimed to investigate the impact of pregnancy and pre-existing comorbidities on COVID-19 infections and associated complications of hospitalisation and mortality in women of reproductive age (WRA). The study also compared the risk of severe COVID-19 complications between pregnant women (PW) and non-pregnant women (NPW) with and without pre-existing comorbidities. Special focus was placed on some understudied comorbidities of immunosuppression, chronic renal disease and chronic obstructive pulmonary disease (COPD). Methods The study utilized anonymized patient-related information for a population of 7,342,869 WRA from the Mexican Ministry of Health data repository on COVID-19. Descriptive variables were characterized using frequencies, percentages, means, and standard deviations. Adjusted odds ratios (aORs) were used to assess the associations between risk factors and outcomes of hospitalisation and mortality. The study covered the entire COVID-19 pandemic period from January 30, 2020, to May 5, 2023. Results The findings revealed that PW were not more likely to get COVID-19 infections than NPW. PW with COVID-19 infections were more likely to require hospital admission, intubation treatments, and ICU admission compared to NPW with COVID-19. PW with immunosuppression had an increased odds ratio (aOR) of getting COVID-19 infections compared to NPW (PW: aOR = 1.0396; NPW: aOR = 0.8373). NPW with immunosuppression had higher risk of mortality (all-cause death: aOR = 1.7084; COVID-19-associated death: aOR = 1.4079) and hospitalisation (all-cause hospitalisation: aOR = 4.1328; COVID-19-associated hospitalisation: aOR = 3.0451) than NPW without immunosuppression. Renal disease was identified as a concerning pre-existing condition that increased the risks of COVID-19 associated mortality/hospitalizations and all-cause mortality/hospitalizations for both PW and NPW. NPW with renal disease had much higher odds ratio (aOR) of either COVID-19-associated-hospitalisations (NPW: aOR = 8.639; PW: aOR = 1.7603) or all-cause hospitalisations (NPW: aOR = 8.8594; PW: aOR = 1.786) than PW with renal disease. Conclusions This study provides valuable insights into the impact of pregnancy and pre-existing comorbidities on COVID-19 outcomes in WRA. The findings underscore the importance of considering demographic factors and pre-existing comorbidities in the management of PW with COVID-19. The study also highlights the need for further research to understand the unique impacts of different comorbidities, particularly immunosuppression and renal disease, on COVID-19 outcomes in WRA.
COVID-19 during pregnancy means 10 times higher risk of ICU admission, Canadian data suggests
Canadian data suggests people who are pregnant face significantly higher risks of serious COVID-19 requiring hospitalization, ICU admission, or life support — a particular concern because pregnant people tend to have lower rates of vaccination.
Since first being identified in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an etiological agent behind Coronavirus disease 19 (COVID-19), has caused three waves of a global pandemic, with a fourth in progress. ...
COVID disinformation and extremism are on the rise in New Zealand. What are the risks of it turning violent?
Nearly a year ago, New Zealand’s intelligence services warned of the ‘realistic possibility’ of future COVID-related violent extremism. How concerned should people be now?
Flawed Analysis of New Zealand Data Doesn’t Show COVID-19 Vaccines Killed Millions - FactCheck.org
Data from around the world support the general safety of the COVID-19 vaccines. Some people online, however, incorrectly claim that illegally obtained data from New Zealand show the vaccines have killed 13 million people worldwide. Experts say the analysis is bogus.
American vaccine disinformation used as ‘Trojan horse’ for far right in New Zealand
“When you reduce the quality of discourse down to street-fighting level,” it can raise the risk of violence, said a former consultant to U.S. intelligence services.
'Thirty-, 40- and 50-year-olds shouldn't be dying at this level': A day in a Victoria ICU
On any given day in B.C., the large majority of people in hospital intensive care units are unvaccinated. On Nov. 5, 59 of 64 COVID patients age 59 and younger in I…
Public Health Ontario COVID-19 data showing vaccines provide ‘high degree’ of protection
Officials said 3.9 per cent of the 400,413 COVID-19 cases between Dec. 14 and June 26 involved partially vaccinated individuals and 0.4 per cent were in those fully immunized.
New vaccine technology could protect from future viruses and variants
Studies of a ‘future-proof’ vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals. The
‘All-In-One’ Vaccine Could Protect Against Future Covid-19 Variants, Researchers Say
Researchers from the California Institute of Technology say the “mosaic-8” vaccine could protect people from other coronaviruses, including SARS and MERS.
China’s mRNA Vaccine Industry: A Latecomer's Prospects
Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic alternatives, China and its sizeable biopharma industry now face a challenging path ahead to catch up to…
Pregnant people with COVID-19 are at increased risk of severe illness and death compared
with non-pregnant females of reproductive age (aged 15–49 years).1 Additionally, COVID-19
during pregnancy is associated with increased risk for adverse pregnancy outcomes,
such as preterm birth and stillbirth.1 When mRNA COVID-19 vaccines first became available
in December, 2020, safety data in pregnancy were limited because pregnant people were
excluded from pre-authorisation clinical trials.2 Lack of data and safety concerns
contributed to initially low uptake among pregnant people, which continues to be lower
than uptake among non-pregnant females of reproductive age.
Complications of COVID-19 Vaccines during Pregnancy; a Systematic Review
Rare serious complications have been documented after COVID-19 vaccination as clinical research proceeded and new target populations, such as children and pregnant women, were included. In this study, we attempted to review the literature relevant ...
Here's the science behind the COVID vaccine in pregnancy
Existing evidence on the safety and efficacy of getting a COVID vaccine in pregnancy all points the same way: the shot is important for maternal and fetal health.
COVID-19 vaccine side-effects less likely in pregnant people, says study
Pregnant people experienced lower rates of side-effects from the COVID-19 vaccine than their counterparts who weren't pregnant, a new Canadian study suggests.
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
Safety data from more than 298 million doses of mRNA COVID-19 vaccine administered
in the first 6 months of the US vaccination programme show that most reported adverse
events were mild and short in duration.